This website is intended only for United States healthcare professionals; if you are not a United States healthcare professional, please visit www.BioMarin.com
This website was developed and funded by BioMarin and is intended for healthcare professionals only. It offers a non-exhaustive selection of materials, including but not limited to publications, presentations, posters and educational materials, to support scientific exchange.
Clinical study results reflect knowledge at the study’s completion and may not be current. Review the methodology, limitations, and authors’ financial disclosures for details.
The information on this website is not medical advice and should not replace independent medical judgment or further research. Content on investigational therapeutics or uses of approved products does not confirm safety or efficacy. BioMarin does not endorse off-label use of its medicines.
As product information may vary by country, please refer to your local health authority regulations and respective approved product information for indications and safety details.

Topics

Learn about hypochondroplasia topics

Burden of Disease

Poster

  • Congresses
  • Hypochondroplasia
  • International Conference on Children’s Bone Health (ICCBH)
  • 2024
  • Burden of Disease

Comorbidity and mortality burden among patients with hypochondroplasia in England between 1998-2019

Mechanism of Action

Resource

  • Educational Materials
  • Hypochondroplasia
  • Mechanism of Action

What is Hypochondroplasia?

Safety and Efficacy Profile

Poster

  • Congresses
  • Hypochondroplasia
  • Pediatric Endocrine Society (PES)
  • 2025
  • Safety and Efficacy Profile

IGF-1 Values in Hypochondroplasia and Effects of Vosoritide

Presentation

  • Congresses
  • Hypochondroplasia
  • European Society for Paediatric Endocrinology (ESPE)
  • 2024
  • Safety and Efficacy Profile

FC5: Growth and Syndromes Phase 2 Trial of Vosoritide Use in Patients with Hypochondroplasia: Pharmacokinetic/ Pharmacodynamic Analysis from 12 Month Data

Presentation

  • Congresses
  • Hypochondroplasia
  • International Skeletal Dysplasia Society (ISDS)
  • 2024
  • Safety and Efficacy Profile

Vosoritide Increases Growth Velocity in Hypochondroplasia: Phase 2 Trial Results

Publication

  • Publications
  • Hypochondroplasia
  • Safety and Efficacy Profile

Vosoritide treatment for children with hypochondroplasia: a phase 2 trial

Resource

  • Congresses
  • Hypochondroplasia
  • American College of Medical Genetics & Genomics (ACMG)
  • 2024
  • Safety and Efficacy Profile

Vosoritide Increases Growth Velocity in Hypochondroplasia: Phase 2 Trial Results